Difference between revisions of "Part:BBa K404114"
VolkerMorath (Talk | contribs) |
|||
(2 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
<partinfo>BBa_K404114 short</partinfo> | <partinfo>BBa_K404114 short</partinfo> | ||
+ | <br /> | ||
+ | {| style="color:black" cellpadding="6" cellspacing="1" border="2" align="right" | ||
+ | ! colspan="2" style="background:#66bbff;"|[https://parts.igem.org/Part:BBa_K404114 [AAV2]-left-ITR_pCMV] | ||
+ | |- | ||
+ | ! colspan="2"|[[Image:Freiburg10_Vectorplasmid precursors 1.png|200px]] | ||
+ | |- | ||
+ | |'''BioBrick Nr.''' | ||
+ | |[https://parts.igem.org/Part:BBa_K404114 BBa_K404114] | ||
+ | |- | ||
+ | |'''RFC standard''' | ||
+ | |[https://parts.igem.org/Help:Assembly_standard_10 RFC 10] | ||
+ | |- | ||
+ | |'''Requirement''' | ||
+ | |pSB1C3<br> | ||
+ | |- | ||
+ | |'''Source''' | ||
+ | |pAAV_MCS provided by Stratagene | ||
+ | |- | ||
+ | |'''Submitted by''' | ||
+ | |[http://2010.igem.org/Team:Freiburg_Bioware FreiGEM 2010] | ||
+ | |} | ||
+ | <br /> | ||
+ | |||
+ | [[Image:Freiburg10_Vectorplasmid precursors 1.png|left|thumb|480px]]<br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /><br /> | ||
+ | <html> | ||
+ | <head> | ||
+ | <meta http-equiv="Content-Type" | ||
+ | content="text/html; charset=windows-1252"> | ||
+ | <meta name="Generator" | ||
+ | content="Microsoft Word 14 (filtered)"> | ||
+ | <style> | ||
+ | <!-- | ||
+ | /* Font Definitions */ | ||
+ | @font-face | ||
+ | {font-family:Calibri; | ||
+ | panose-1:2 15 5 2 2 2 4 3 2 4;} | ||
+ | /* Style Definitions */ | ||
+ | p.MsoNormal, li.MsoNormal, div.MsoNormal | ||
+ | {margin-top:0cm; | ||
+ | margin-right:0cm; | ||
+ | margin-bottom:10.0pt; | ||
+ | margin-left:0cm; | ||
+ | line-height:115%; | ||
+ | font-size:11.0pt; | ||
+ | font-family:"Calibri","sans-serif";} | ||
+ | p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph | ||
+ | {margin-top:0cm; | ||
+ | margin-right:0cm; | ||
+ | margin-bottom:10.0pt; | ||
+ | margin-left:36.0pt; | ||
+ | line-height:115%; | ||
+ | font-size:11.0pt; | ||
+ | font-family:"Calibri","sans-serif";} | ||
+ | p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst | ||
+ | {margin-top:0cm; | ||
+ | margin-right:0cm; | ||
+ | margin-bottom:0cm; | ||
+ | margin-left:36.0pt; | ||
+ | margin-bottom:.0001pt; | ||
+ | line-height:115%; | ||
+ | font-size:11.0pt; | ||
+ | font-family:"Calibri","sans-serif";} | ||
+ | p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle | ||
+ | {margin-top:0cm; | ||
+ | margin-right:0cm; | ||
+ | margin-bottom:0cm; | ||
+ | margin-left:36.0pt; | ||
+ | margin-bottom:.0001pt; | ||
+ | line-height:115%; | ||
+ | font-size:11.0pt; | ||
+ | font-family:"Calibri","sans-serif";} | ||
+ | p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast | ||
+ | {margin-top:0cm; | ||
+ | margin-right:0cm; | ||
+ | margin-bottom:10.0pt; | ||
+ | margin-left:36.0pt; | ||
+ | line-height:115%; | ||
+ | font-size:11.0pt; | ||
+ | font-family:"Calibri","sans-serif";} | ||
+ | span.apple-style-span | ||
+ | {mso-style-name:apple-style-span;} | ||
+ | .MsoChpDefault | ||
+ | {font-family:"Calibri","sans-serif";} | ||
+ | .MsoPapDefault | ||
+ | {margin-bottom:10.0pt; | ||
+ | line-height:115%;} | ||
+ | @page WordSection1 | ||
+ | {size:612.0pt 792.0pt; | ||
+ | margin:70.85pt 70.85pt 2.0cm 70.85pt;} | ||
+ | div.WordSection1 | ||
+ | {page:WordSection1;} | ||
+ | --> | ||
+ | </style> | ||
+ | </head> | ||
+ | <body lang="EN-US"> | ||
+ | <div class="WordSection1"> | ||
+ | <p class="MsoNormal"><span class="apple-style-span"><b><u><span | ||
+ | style="font-size: 14.5pt; line-height: 115%; font-family: "Arial","sans-serif";">[AAV2]-left-ITR_pCMV</span></u></b></span></p> | ||
+ | <p class="MsoNormal" style="text-align: justify;"><span | ||
+ | style="font-size: 10pt; line-height: 115%;">Producing | ||
+ | recombinant virus particles for therapeutical applications | ||
+ | is, besides specific cell targeting, purification and quantification | ||
+ | assays of | ||
+ | AAV-2, one intention of the Virus Construction Kit provided by the iGEM | ||
+ | team | ||
+ | Freiburg_Bioware 2010. For obtaining a modular toolkit, the complex | ||
+ | biological | ||
+ | system of the Adeno-associated virus serotype 2 was examined by an | ||
+ | exhaustive | ||
+ | literature search. Subsequently, the essential components for AAV-2 | ||
+ | particle | ||
+ | production were extracted and redesigned to match the iGEM standard.</span></p> | ||
+ | <p class="MsoNormal" style="text-align: justify;"><span | ||
+ | style="font-size: 10pt; line-height: 115%;">The provided | ||
+ | tripartite system is independent of a | ||
+ | superinfection of Adeno- or herpes simplex viruses since the | ||
+ | genes encoding | ||
+ | the required helper-proteins are co-transfected. Inside the eukaryotic | ||
+ | host | ||
+ | cell, the DNA sequence containing the inverted terminal repeats (ITRs) | ||
+ | is extracted | ||
+ | and later encapsidated into the preformed capsids after production of | ||
+ | single-stranded DNA. Consequently, this plasmid is known as the vector | ||
+ | plasmid | ||
+ | (pGOI). Promoter, <i>beta-globin</i> intron and the hGH | ||
+ | terminator signal are | ||
+ | flanked by the ITRs (ITRs, BBa_K404100 and BBa_K404101) and regulate | ||
+ | transgene | ||
+ | expression. The vector plasmid containing the desired gene of interest | ||
+ | is | ||
+ | cotransfected with the RepCap plasmid (BBa_K404001, BBa_K404002 or | ||
+ | BBa_K404003) | ||
+ | and the pHelper plasmid. To obtain the fully assembled vector plasmid, | ||
+ | several | ||
+ | assembly steps have to be performed. </span></p> | ||
+ | <p class="MsoNormal" style="text-align: justify;"><span | ||
+ | style="font-size: 10pt; line-height: 115%;">Facilitating the | ||
+ | cloning steps, the iGEM team | ||
+ | Freiburg_Bioware 2010 provides the 5´nucleotide components in respect | ||
+ | to the | ||
+ | desired gene of interest, consisting of the left inverted terminal | ||
+ | repeat (</span><span | ||
+ | style="font-size: 10pt; line-height: 115%;">BBa_K404100</span><span | ||
+ | style="font-size: 10pt; line-height: 115%;">) followed by | ||
+ | the CMV promoter (</span><span | ||
+ | style="font-size: 10pt; line-height: 115%;">BBa_K404102).</span></p> | ||
+ | <p class="MsoNormal"> </p> | ||
+ | </div> | ||
+ | </body> | ||
+ | </html> | ||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
− | |||
<!-- Add more about the biology of this part here | <!-- Add more about the biology of this part here |
Latest revision as of 15:48, 27 October 2010
[AAV2]-left-ITR_pCMV
[AAV2-left-ITR_pCMV] | |
---|---|
BioBrick Nr. | BBa_K404114 |
RFC standard | RFC 10 |
Requirement | pSB1C3 |
Source | pAAV_MCS provided by Stratagene |
Submitted by | [http://2010.igem.org/Team:Freiburg_Bioware FreiGEM 2010] |
[AAV2]-left-ITR_pCMV
Producing recombinant virus particles for therapeutical applications is, besides specific cell targeting, purification and quantification assays of AAV-2, one intention of the Virus Construction Kit provided by the iGEM team Freiburg_Bioware 2010. For obtaining a modular toolkit, the complex biological system of the Adeno-associated virus serotype 2 was examined by an exhaustive literature search. Subsequently, the essential components for AAV-2 particle production were extracted and redesigned to match the iGEM standard.
The provided tripartite system is independent of a superinfection of Adeno- or herpes simplex viruses since the genes encoding the required helper-proteins are co-transfected. Inside the eukaryotic host cell, the DNA sequence containing the inverted terminal repeats (ITRs) is extracted and later encapsidated into the preformed capsids after production of single-stranded DNA. Consequently, this plasmid is known as the vector plasmid (pGOI). Promoter, beta-globin intron and the hGH terminator signal are flanked by the ITRs (ITRs, BBa_K404100 and BBa_K404101) and regulate transgene expression. The vector plasmid containing the desired gene of interest is cotransfected with the RepCap plasmid (BBa_K404001, BBa_K404002 or BBa_K404003) and the pHelper plasmid. To obtain the fully assembled vector plasmid, several assembly steps have to be performed.
Facilitating the cloning steps, the iGEM team Freiburg_Bioware 2010 provides the 5´nucleotide components in respect to the desired gene of interest, consisting of the left inverted terminal repeat (BBa_K404100) followed by the CMV promoter (BBa_K404102).
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]